Christopher Haqq
2022 - Elicio Therapeutics
In 2022, Christopher Haqq earned a total compensation of $1.2M as Executive Vice President, Head of Research and Development and Chief Medical Officer at Elicio Therapeutics.
Compensation breakdown
| Non-Equity Incentive Plan | $186,010 |
|---|---|
| Option Awards | $511,321 |
| Salary | $465,025 |
| Total | $1,162,356 |
Haqq received $511.3K in option awards, accounting for 44% of the total pay in 2022.
Haqq also received $186K in non-equity incentive plan and $465K in salary.
Rankings
In 2022, Christopher Haqq's compensation ranked 2,752nd out of 5,760 executives tracked by ExecPay. In other words, Haqq earned more than 52.2% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 2,752 out of 5,760 | 52nd |
Division Manufacturing | 1,529 out of 3,136 | 51st |
Major group Chemicals And Allied Products | 707 out of 1,422 | 50th |
Industry group Drugs | 659 out of 1,323 | 50th |
Industry Pharmaceutical Preparations | 476 out of 969 | 51st |
Source: SEC filing on September 27, 2024.
Haqq's colleagues
We found three more compensation records of executives who worked with Christopher Haqq at Elicio Therapeutics in 2022.